Shares of Pfizer Ltd surged 7% to touch a day’s high of Rs 4,444 on 24th February after the firm signed a domestic marketing and sale pact for two brands with Mylan Pharma, namely Ativan and Pacitane.

The agreement is for five years and aims to enhance distribution and clinic presence, with the drugs possibly sourced from Mylan’s Indian manufacturing hubs or imported from its global network.

Mylan has a strong presence in central nervous system therapy, with skilled resources for neurologists and psychiatrists, while Pfizer considers both brands to be market leaders.

Pacitane holds a 67% market share in its category, while Ativan commands a 6% share in the Benzodiazepine Tranquilizer market despite facing supply shortages.

Pfizer Limited previously transferred some off-patented and generic medicines to Mylan Pharma for Rs 180.48 crore in FY22 under a business transfer agreement.

The firm reaffirmed its 2025 revenue guidance of $61-64 billion, aiming to return to pre-pandemic operating margins. Indian pharma closely watches US trade policies amid concerns over reciprocal tariffs on Indian exports worth $8 billion.

At 10:51 AM, the shares of Pfizer were trading 6.10% higher at Rs 4,345 on NSE.

Curious About Pfizer? Ask the Analyst.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!